See the latest news and media coverage for Fate Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing cell therapies
fatetherapeutics.comLast updated
In short: Fate Therapeutics initiated a Phase 2 trial for lupus nephritis, received FDA clearance for FT839, and reported strong Q2 2026 results.
The open-label study will enroll approximately 53 refractory patients to evaluate complete renal response at week 26, advancing the therapy toward accelerated regulatory approval.
The company dosed its first patient in a phase 2 lupus nephritis trial, secured FDA clearance for its next-generation CAR-T candidate, and reported a cash runway extending into 2028.
The company grants stock options and restricted stock units to three newly hired non-executive employees, with all equity vesting over four years.
The company recently received FDA authorization to proceed with a Phase 1 trial evaluating the safety and efficacy of this cell therapy in multiple B cell-mediated conditions.
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819...
LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge FDA...
Investing.com - Fate Therapeutics (NASDAQ: FATE) reported second quarter EPS of $-0.250, $0.02 better than the analyst estimate of $-0.270.
Fate Therapeutics has seen improvements in four patients with treatment-resistant systemic sclerosis who were dosed with | “We were not expecting to see clinical responses...
Track Fate Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Fate Therapeutics and other trending companies.